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Abstract  
Context: Symptoms affect quality of life (QOL), functional status, and cognitive function in 
cancer survivors, but older survivors are understudied. 
Objectives: To identify prototypical pre-systemic therapy psychoneurological symptom clusters 
among older breast cancer survivors, and determine whether these symptom clusters predicted 
cognition and QOL over time. 
Methods: Women with newly diagnosed non-metastatic breast cancer (n=319) and matched 
non-cancer controls (n=347) aged 60+ completed questionnaires and neuropsychological tests 
before systemic therapy and 12- and 24-months later. Latent class analysis identified clusters of 
survivors based upon their pre-therapy depression, anxiety, fatigue, sleep disturbance, and pain. 
Linear mixed-effects models examined changes in objective cognition, perceived cognition, and 
functional status (instrumental activities of daily living (IADL) disability, functional well-being, 
and breast cancer-specific QOL) by group, controlling for covariates.  
Results:  Nearly one-fifth of older survivors were classified as having a high pre-therapy 
symptoms (n=51; 16%); the remainder had a low symptoms (n=268; 84%); both groups 
improved over time on all outcomes. However, compared to the low symptom group and 
controls, survivors with high symptoms had lower baseline objective cognition  and lower 
perceived cognition at baseline and 24-months, lower functional well-being at baseline  and 12-
months, greater IADL disability at baseline, and lower breast cancer-specific QOL at all time 
points (all p<0.05).  
Conclusion: Nearly one-fifth of older breast cancer survivors had high psychoneurological 
symptoms at diagnosis, which, predict clinically meaningful decrements in perceived cognition 
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and function in the first 24 months post-diagnosis. Pre-treatment psychoneurological symptom 
clusters could identify survivors for monitoring or intervention.  
 
Key Words: symptoms, symptom cluster, geriatric assessment, cognition, quality of life 
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Introduction 
Anxiety, depression, fatigue, sleep disturbance, and pain are prevalent and distressing 
psychoneurological symptoms1-3 that have individually been associated with cognitive problems 
such as difficulties with concentration, decision-making, and memory in cancer survivors.6,7 
Older survivors may be at particularly high risk for these symptoms, as well as adverse cognitive 
function and quality of life (QOL) outcomes due to concurrent forces of aging, comorbid 
conditions, and risk for neurodegeneration.7,8 Psychoneurological symptoms often co-occur, or 
cluster, and their combined effects on QOL can be greater than the sum of their individual 
effects.9-17 Psychoneurological symptom clusters and cognitive problems appear to share some 
common underlying mechanisms such as proinflammatory cytokines, hormone dysregulation, 
and genetic vulnerabilities.10-12,14,18-20 These observations lead some to suggest that cognitive 
problems are part of the psychoneurological symptom cluster;10,14 however, psychoneurological 
symptoms prior to systemic treatment may be a risk factor for subsequent cognitive dysfunction 
as well as poor QOL.6,7 Cancer survivors, especially older cancer survivors (ages 60+), are 
particularly concerned about cognitive problems as an outcome of their health conditions.2,21,22  
Despite the fact that 74% of the 15.5 million US cancer survivors are aged 60 and older,23 
there is a paucity of symptom research focused on older survivors.  An early study in this area 
found that older breast cancer survivors have significantly greater anxiety, depression, and 
fatigue prior to systemic cancer treatment than matched cancer-free controls at the same time 
point.24 Although these symptoms were not associated with baseline objective cognitive 
function,24 the longitudinal relationships between pre-treatment psychoneurological symptom 
clusters and subsequent cognitive functioning, functional status, and QOL have yet to be 
examined. This evidence would be important to help identify subgroups of older breast cancer 
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survivors who may be at risk for poor functional outcomes, in order to inform potential 
intervention targets and survivorship care planning for older survivors as they age. 
We used data from the longitudinal Thinking and Living with Cancer (TLC) study of 
older breast cancer survivors and matched cancer-free controls to address these knowledge 
gaps.24 In this report we evaluate whether pre-systemic treatment symptom clusters are 
associated with cognition and QOL outcomes over time. We hypothesized that older survivors 
with high pre-treatment symptoms would have worse objective and perceived cognitive function, 
greater functional disability, and poorer breast cancer-specific QOL relative to those with low 
symptoms and matched non-cancer controls.  
Methods 
This is a secondary analysis of data from the longitudinal multisite TLC study, which was 
established to examine cognitive function in older breast cancer survivors.24  Participants 
included in the current analyses were recruited from five sites from August 2010 to December 
2015; recruitment and follow-up are ongoing. The research protocol was registered at 
ClinicalTrials.gov (#NCT03451383), met Health Insurance Portability and Accountability 
(HIPAA) standards, and was approved by all institutional review boards (IRBs). 
Participants 
Participants were aged >60 years and fluent in English. Survivors were newly diagnosed 
with primary non-metastatic breast cancer (stages 0-III). Controls were frequency-matched to 
survivors based on age (in 5-year groups), race (i.e., White, Black/African American, Hispanic, 
and Asian American/Pacific Islander), education (i.e., ≤high school, some college+), and site. 
Participants were excluded if they had a stroke, head injury, major psychiatric disorder or 
neurodegenerative disorder, prior chemotherapy or hormonal therapy, or treatment for another 
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cancer within the past five years. Those taking psychoactive medications were eligible if the 
dose was stable for at least two months prior to enrollment.  
Among those eligible, 36.2% of survivors and 97.6% of controls consented (Figure 1). 
Survivors’ consent rates varied across sites from 17.2-72.7% (median 62.5%), with the lowest 
consent rate at a large urban cancer center that had many competing research studies. 
Participants were screened after informed consent to ensure ability to complete the study and 
were ineligible if they scored <24 on the Mini-Mental State Examination (MMSE) or <3rd grade 
on the Wide Range Achievement Test-4th Edition (WRAT-4); one survivor and one control were 
excluded for these reasons. The analytic sample included 319 breast cancer survivors and 347 
controls. 
Data Collection 
 Data collection procedures have been described previously.24 Survivors completed 
baseline assessment before radiation or systemic therapy and after surgery (except for seven 
treated with neo-adjuvant therapy). Survivors’ medical records were reviewed for clinical data, 
including subsequent recurrences. Biospecimens were collected for APOE genotyping.25,26 
Follow-up assessments were conducted at 12- and 24-months post-enrollment. Controls were 
assessed contemporaneously. Assessments included in-person neuropsychological testing and an 
in-person or telephone interview.  
Measures 
Outcomes 
The battery of neuropsychological assessments used in this study has been previously 
described.27,28 Two cognitive domains were assessed: attention/processing speed/executive 
function (APE; six tests: Neuropsychological Assessment Battery [NAB] digits forward, NAB 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Symptoms in Older Breast Cancer Survivors 9 
 
digits backward, Controlled Oral Word Association Test, Trail making A, Trail making B, and 
Digit Symbol Coding; baseline, 12- and 24-month Cronbach’s α=0.66-0.72)29,30 and 
learning/memory (LM; five tests: Logical memory I, Logical memory II, NAB list learning 
immediate recall, NAB list learning short delay, NAB list learning long delay; α=0.85-0.90).27,31 
These domains were selected because they are affected in cancer,32 can change over time,33 and 
are relevant to aging.34 Raw scores from neuropsychological tests were standardized to the 
means and standard deviations for age and education strata-matched control scores at baseline.28 
Domain scores were created from the standardized z-scores for each test. 
Self-reported outcomes included: 1) Perceived cognitive function assessed with the 
Functional Assessment of Cancer Therapy-Cognitive Function35 (FACT-Cog; α=0.95-0.96; 
scores range from 0-148; minimal clinically important difference (MCID)=7-10 points36); 2) 
Instrumental Activities of Daily Living (IADL) Disability assessed using the Older Americans 
Resource Scale37 (OARS; scores range from 1-7; MCID=3 points38); 3) The functional well-
being (FWB) subscale of the FACT-B (or FACT-G for controls)39 assessed ability to function, 
do work, and enjoy activities (α=0.79-0.87; scores range from 6-24; MCID=2-3 points;40 one 
item addressing sleep was excluded to limit overlap with sleep measure); 4) The Breast Cancer 
Subscale (BCS) of the FACT-B assessed quality of life (QOL) attributable to breast cancer 
concerns (α=0.42-0.75; scores range from 9-45; MCID=2-3 points;40 one item addressing pain 
was excluded to limit overlap with symptom measures). 
Predictors  
Symptoms of anxiety, depression, fatigue, sleep disturbance, and pain were selected a 
priori based on prior research.9 Anxiety was assessed with the State-Trait Anxiety Inventory 
(STAI; α=0.86). Depression was assessed with the Center for Epidemiological Studies-
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Depression (CES-D) scale, excluding the item on sleep problems (α=0.86). Fatigue was assessed 
with the FACIT-F (α=0.90). Assessments of sleep problems and pain were adapted from the 
FACT-B and CES-D. Sleep problems were assessed by participants’ 5-point Likert-scale ratings 
on two questions: “I have been sleeping well in the past week” and “My sleep was restless in the 
past week” (α=0.78). Pain was assessed on a 5-point Likert-scale with two questions: “I have had 
pain in the past week” and “I have had certain parts of my body where I experience pain” 
(α=0.77). Higher scores on each symptom measure indicated higher symptom levels, and scores 
were scaled to T-scores based on control means and standard deviations. 
Covariates 
Covariates were determined a priori. Cancer stage and treatments were collected from 
medical records. Cancer stage was coded stage 0-1 vs. 2-3. There was little variability in 
treatment type, dosage, or duration; therefore, treatment was coded as chemotherapy with or 
without hormone therapy and vs. hormone therapy alone. Demographics included age, education, 
and race. Self-reported comorbidities were assessed using the OARS comorbidity scale.24 APOE 
genotype26 was determined by standard single nucleotide polymorphism (SNP) genotyping. 
APOE genotype status was categorized as carrier (presence of any ε4 allele) vs. non-carrier (no 
ε4 alleles). The WRAT-4 was used to measure cognitive reserve.41 Study site was also included 
as a covariate due to the variability in survivors’ consent rates across sites. 
Statistical Analyses 
 Demographic and clinical characteristics of survivors and controls were compared with t 
and χ2 tests. Latent class analysis was performed in Mplus42 and used to identify groups of 
survivors with high versus low symptoms. Models were run iteratively and the Vuong-Lo-
Mendell-Rubin Likelihood (VLMR) Likelihood ratio test43 was used to determine the number of 
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symptom cluster groups among survivors.  Model entropy is also reported, with values above 
0.80 indicating a good fitting solution. 
Linear mixed-effects models predicting objective cognition, perceived cognition and 
functional scores over time (APE, LM, FACT-Cog, FACT-FWB, and IADLs) examined 
differences between symptom and control groups on outcomes and the group-by-time 
interaction, adjusting for age, race, cognitive reserve, site, comorbidity, and APOE status (any + 
vs. no ε4). Among survivors, linear mixed-effects models also examined concurrent and 
longitudinal associations of symptom group with FACT-BCS score and group-by-time 
interactions, adjusting for covariates plus stage and treatment. Maximum likelihood estimation 
was employed to use all available data.  
Results 
 Participants ranged in age from 60-98 (Table 1). Survivors and controls were similar in 
baseline demographics, cognitive reserve, comorbidities, APOE genotype, and objective and 
perceived cognitive function.  
Symptom Clusters in Survivors 
 The results of the latent class analysis indicated that a two-group solution fit the data 
better than a one-group model (VLMR p<0.001, Entropy=0.946).  Although the entropy was 
good for the three-group solution (0.911), the VLMR indicated that it did not provide a 
statistically better fit to the data (p=0.504).  Therefore, the two-group solution was considered as 
final. The high symptom group included 16% (n=51) and the low symptom group 84% (n=268) 
of survivors. The symptom groups among survivors were significantly different on all five 
individual symptoms (p<0.05); however, the low symptom group had similar symptom T-scores 
to controls (Figure 2). Compared to the low symptom group, the high symptom group had lower 
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average WRAT-4 scores, greater total comorbidities, was more likely to have later stage disease, 
and was less likely to receive chemotherapy with or without hormone therapy (Table 1) (all 
p<0.05).  
Cognition Outcomes 
The high symptom group had statistically lower baseline APE (p=0.025) and LM 
(p=0.018) scores than the control group (Table 2). All groups showed improvement in 
neuropsychological scores over time (APE p<0.0001; LM p<0.0001; Figures 3a, 3b). There were 
no significant symptom cluster group-by-time interactions.   
Perceived cognition (FACT-Cog) was similar at baseline between the low symptom and 
control groups, but the high symptom group had statistically and clinically meaningful worse 
baseline perceived cognitive scores than controls (high: 116.91, controls: 132.19, p<0.0001; 
Figure 3c). There was also a significant group-by-time interaction (p=0.007), with perceived 
cognition scores worsening from baseline to 12 months for the low symptom group (p=0.049), 
and improving in the high symptom group (p=0.007). Despite improvement for the high 
symptom group, 95% confidence intervals (CI) of adjusted means (Table 3) showed that the high 
symptom group reported statistically and clinically worse perceived cognition than the control 
group at 12 months (high: 124.60, controls: 132.14, p<0.05) and both groups at 24 months (high: 
119.66, low: 130.70, controls: 131.83, p<0.05). 
 Functional Outcomes 
  For functional well-being QOL (FACT-FWB; Figure 4a), controls exhibited significantly 
better scores at baseline than the low (p=0.005) and high symptom groups (p<0.0001). All 
groups showed improvement over time (p<0.0001). The group-by-time interaction was 
statistically significant (p<0.0001); controls maintained functional well-being QOL over time, 
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and there was improvement from baseline to 12 and 24 months for the low (12 months: p=0.012; 
24 months: p=0.012) and high (12 months: p<0.0001; 24 months: p<0.0001) symptom groups. 
Despite this improvement, scores remained statistically and clinically worse for the high 
compared to the low symptom group and controls at 12 months (high: 14.59, low: 17.22, 
controls: 17.12, p<0.05), but the statistically significant difference was not clinically significant 
at 24 months (high: 15.75, low: 17.33, controls: 17.16, p<0.05).    
 At baseline, controls and the low symptom group had similar IADL disability scores to 
each other, but the high symptom group had greater IADL disability (p<0.0001; Figure 4b). All 
groups showed improvement over time (p<0.001). The group-by-time interaction was 
statistically significant (p<0.0001), with the high symptom group showing greater improvement 
in IADL disability from baseline at 12 (p<0.0001) and 24 months (p<0.0001) than the low 
symptom group and controls. Despite this improvement, the high symptom group did not differ 
from the low symptom group and controls at 12 (high: 0.61, low: 0.24, controls: 0.23, p>0.05) or 
24 months (high: 0.45, low: 0.27, controls: 0.29, p>0.05). 
Breast Cancer-Specific QOL 
 The high symptom group exhibited statistically and clinically meaningful worse baseline 
breast cancer QOL than the low symptom group (Table 4; Figure 4c). Both groups significantly 
improved over time (p<0.0001). The group-by-time interaction was significant (p<0.0001). 
Relative to the low symptom group, the high symptom group showed significantly improved 
scores from baseline to 12 months (p=0.001) and 24 months (p=0.002). However, the high 
symptom group remained statistically and clinically lower than the low symptom group at 
baseline (high: 22.87, low: 29.61, p<0.05), 12 (high: 26.82, low: 30.03, p<0.05), and 24 months 
(high: 27.09, low: 30.68, p<0.05). 
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Discussion 
 This study is among the first to examine the relationship between pre-treatment symptom 
clusters and longitudinal cognitive and functional outcomes over two years in a large prospective 
study of older breast cancer survivors and matched cancer-free controls. Nearly one-fifth of older 
breast cancer survivors reported high symptoms before systemic therapy. Despite some 
improvement over time, high pre-treatment symptoms were significantly associated with 
persistently worse perceived cognition and breast cancer specific QOL scores. Additionally, the 
high symptom group had lower objective cognition at baseline than non-cancer controls. In 
contrast, the low symptom group appeared similar to matched non-cancer controls on all 
outcomes across time. 
 Our findings for older breast cancer survivors converge with prior research showing that 
a subgroup of survivors report initial high levels of anxiety, depression, fatigue, sleep 
disturbance, and pain.9 Prior data also support a relationship between high (vs. low) symptoms 
and worse QOL and functional status, with similar effect sizes as seen in our sample.14-17 The 
number of survivors in the high symptom group is also similar to prior research (14-28%) in 
survivors from diverse age groups.16,17,44,45 Although we expected older survivors to experience 
greater pre-treatment symptoms due to aging, prior findings indicate that younger survivors are 
more likely than older survivors to report high symptoms.16,45 Potentially, older survivors may 
generally report low levels of symptoms due to a shift in their pattern of responding as they 
become accustomed to age-related physical ailments.46     
Specific symptoms of anxiety, depression, fatigue, and sleep disturbance have each been 
independently associated with worse perceived cognition in cancer samples. 7,47,48 Research on 
symptom clusters in cancer occasionally includes cognitive complaints in the cluster because 
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they often co-occur.10,14 However, poor performance on objective tests of cognitive function is 
inconsistently related to these symptoms.49,50 Our findings confirm that these symptoms and self-
reported cognition are associated. The lack of overall effect for objective cognitive function may 
reflect the very subtle changes in these measures over time. Perceived cognitive function, QOL, 
and functional status remain clinically important and should be assessed early in care processes51 
because, beyond QOL and cognition, they predict treatment toxicity and mortality.52  
 Our findings have clinical implications for geriatric assessment and survivorship 
interventions. Assessment of pre-treatment symptomatology as part of a comprehensive geriatric 
assessment may help clinicians identify older cancer survivors at risk for functional impairment 
and worse QOL. Although our results indicate that those in the high symptom group gradually 
improved over time, lower perceived cognition and QOL persisted over two years in the high 
symptom group. In contrast, survivors in the low symptom group appear similar to women 
without cancer on all outcomes. The ability to distinguish older survivors who are at greatest risk 
prior to treatment from those similar to cancer-free older adults should help providers determine 
which patients are most in need of support. Symptoms at diagnosis may be a promising method 
to help providers identify this potentially higher-risk older survivor group, and make early 
referrals for interventions.   
Initial evidence suggests that cognitive-behavioral therapy (CBT) can reduce severity of 
symptoms such as depression, fatigue, and insomnia; CBT and pharmacological treatment both 
may be effective for treating mood, adjustment, and sleep disorders, and in turn, improve  cancer 
survivors’ QOL and functional status.53-55 Other behavioral interventions may also be effective in 
lowering symptoms, including yoga, meditation, and journaling.56,57 Therefore, providers may 
also consider behavioral interventions to mitigate symptomatology. 
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 Limitations of the current study should be considered. Although the sample of survivors 
was ethnically and racially representative of older cancer survivors in the United States, the 
sample was well-educated and recruited mainly from academic cancer centers and their affiliated 
community sites. Survivors’ consent rates also differed across study sites. Therefore, results may 
not generalize to broadly representative survivor groups. Although the sample was large, the 
small subgroup of survivors with high symptoms may have limited power to detect some 
relationships with outcomes. Attrition may also have limited power. Additionally, assessment of 
symptoms, perceived cognition, IADL disability, and quality of life was self-reported, and any 
systematic error or bias in responses could have affected the magnitude and directions of the 
observed relationships. However, the consistency of associations between symptoms and several 
diverse types of outcomes suggests that results are robust. Measures of sleep disturbance and 
pain were not validated measures, although they showed good internal consistency; and the other 
symptoms were from well validated, reliable scales. Finally, differences in IADLs at baseline did 
not appear to be clinically meaningful according to current benchmarks for older adults; 
however, little is known regarding clinically meaningful differences in subtle IADL difficulties 
for older breast cancer survivors. 
 Overall, nearly one-fifth of older breast cancer survivors in this study experienced high 
symptoms prior to systemic cancer treatment, and being in the high symptom group predicted 
poor outcomes. Identifying older breast cancer survivors who are at risk for cognitive complaints 
and poor QOL has implications for geriatric assessment and referral for interventions to support 
symptom management and mental health. 
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Table 1. Participant Characteristics 
Characteristic 
All Survivors 
(N=319) 
High Symptom 
(N=51) 
Low Symptom 
(N=268) 
Controls 
(N=347) 
Completed 12-month follow-up, n (%) 235 (73.7) 33 (64.7) 202 (75.4) 307 (88.5) 
Completed 24-month follow-up, n (%) 205 (64.3) 29 (56.9) 176 (65.7) 254 (73.2) 
Age, Mean (SD) 68.2 (6.1) 67.5 (5.1) 68.4 (6.3) 67.8 (7.0) 
Race, n (%) 
    Othera 66 (20.7) 13 (25.5) 53 (19.8) 73 (21.0) 
    Non-Hispanic White 253 (79.3) 38 (74.5) 215 (80.2) 273 (78.7) 
Years of Education, Mean (SD) 15.2 (2.2) 14.9 (2.1) 15.2 (2.2) 15.4 (2.3) 
WRAT-4 Standardized Score, Mean (SD) 111.2 (15.4) *107.0 (15.1) 112.0 (15.4) 111.8 (16.1) 
Total Number of Comorbidities, Mean (SD) 2.6 (1.9) *3.2 (2.4) 2.4 (1.8) 2.4 (1.8) 
APOE ε4 Carrier, n (%) 57 (17.9) 9 (17.6) 48 (17.9) 84 (24.2) 
AJCC Stage, n (%)  
    0-1  213 (66.8) *26 (51.0) 187 (69.8) 
n/a 
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    2-3 105 (32.9) *24 (47.1) 81 (30.2) 
Surgery, n (%) 
    Lumpectomy  177 (55.5) 28 (54.9) 149 (55.6) 
    Mastectomy 140 (43.9) 23 (45.1) 117 (43.7) 
Cancer Treatment Received, n (%)  
    Hormonal only 90 (28.2) *21 (41.2) 69 (25.7) 
    Chemotherapy+/-Hormonal 217 (68.0) *30 (58.8) 187 (69.8) 
Radiation Treatment, n (%) 171 (53.6) 27 (52.9) 144 (53.7)  
Pre-treatment Symptom T-score, Mean (SD)      
    Anxiety 51.9 (11.6) *70.4 (14.9) 48.5 (6.5) 48.2 (7.8) 
    Depression 51.8 (11.6) *73.7 (10.7) 47.9 (6.0) 48.3 (7.9) 
    Fatigue 52.3 (12.2) *70.7 (18.2) 48.8 (6.1) 47.8 (6.6) 
    Sleep Disturbance 51.6 (10.5) *61.8 (9.5) 49.7 (9.5) 48.5 (9.3) 
    Pain 50.7 (10.4) *60.4 (12.2) 48.9 (8.9) 49.2 (9.6) 
 
*Significantly different from low symptom group at p<0.05. WRAT-4=Wide Range Achievement Test, 4th edition.  
aOther race includes Black, Hispanic, and American Indian/Alaska Native. Numbers may not add to 100% due to missing data.
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Table 2. Associations with Cognitive and Functional Outcomes in Models with Survivors and Controls 
APE LM FACT-Cog FACT-FWB OARS-IADLs 
Effect β SE β SE β SE β SE β SE 
Intercept 0.14 0.27 0.11 0.35 126.62*** 7.93 15.71*** 1.48 -1.34*** 0.35 
Group - High Symptom -0.20* 0.09 -0.27* 0.11 -15.28*** 2.69 -6.66*** 0.55 0.95*** 0.14 
Group - Low Symptom 0.00 0.05 0.03 0.06 1.01 1.42 -0.82** 0.29 0.11 0.07 
Time - 12 month 0.07*** 0.02 0.18*** 0.03 -0.05 0.88 -0.21 0.23 0.04 0.04 
Time - 24 month 0.13*** 0.02 0.14*** 0.04 -0.36 0.91 -0.18 0.25 0.10 0.05 
GroupXTime - High 
Symptom, 12 month 0.09 0.07 0.19 0.10 7.75** 2.84 4.13*** 0.74 -0.57*** 0.14 
GroupXTime - High 
Symptom, 24 month 0.06 0.08 0.21 0.11 3.11 2.87 5.25*** 0.79 -0.79*** 0.16 
GroupXTime - Low 
Symptom, 12 month 0.03 0.03 -0.03 0.05 -2.74* 1.39 0.92* 0.36 -0.10 0.07 
GroupXTime - Low 
Symptom, 24 month 0.00 0.04 0.07 0.06 -2.13 1.43 0.98* 0.39 -0.13 0.08 
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Age -0.02*** 0.00 -0.03*** 0.00 -0.03 0.10 0.01 0.02 0.02*** 0.00 
Race - other race -0.35*** 0.06 -0.25*** 0.07 0.79 1.63 0.35 0.30 0.02 0.07 
Cognitive Reserve 0.01*** 0.00 0.02*** 0.00 0.08 0.04 0.01 0.01 0.00 0.00 
Comorbidity -0.03** 0.01 0.01 0.02 -1.57*** 0.35 -0.36*** 0.06 0.10*** 0.01 
*p<0.05, **p<0.01, ***p<0.001 
Reference groups: control for group, baseline for time, White for race, ε4 negative for APOE. The models also controlled for study 
site. Estimates for each group by time interaction represent the average difference in rate of change for the respective symptom groups 
relative to the control group after adjusting for covariates.
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Table 3. Adjusted Least Squares Means for Cognitive and Quality of Life Outcomes 
 High Symptom Group Low Symptom Group Controls 
Outcome 
    Time point Mean (95% CI) Mean (95% CI) Mean (95% CI) 
APE scorea  
    Baseline -0.35 (-0.53,-0.18) -0.16 (-0.28,-0.04) -0.16 (-0.27,-0.04) 
    12 months -0.19 (-0.38,0.00) -0.06 (-0.18,0.07) -0.08 (-0.20,0.03) 
    24 months -0.16 (-0.37,0.05)  -0.03 (-0.15,0.10)  -0.02 (-0.14,0.10) 
LM scorea  
    Baseline -0.43 (-0.66,-0.19) -0.12 (-0.27,0.03) -0.15 (-0.30,-0.01) 
    12 months -0.06 (-0.32,0.21)  0.03 (-0.13,0.19)  0.03 (-0.12,0.18) 
    24 months -0.08 (-0.36,0.20)  0.08 (-0.08,0.24) -0.02 (-0.17,0.13) 
Perceived cognitive functionb  
    Baseline 116.91 (111.47,122.34) 133.19 (129.69,136.70) 132.19 (128.80,135.58) 
    12 months 124.60 (118.40,130.80) 130.40 (126.76,134.04) 132.14 (128.72,135.55) 
    24 months 119.66 (113.08,126.24) 130.70 (126.90,134.50) 131.83 (128.29,135.36) 
Functional well-beingc  
    Baseline 10.68 (9.59,11.76) 16.52 (15.85,17.19) 17.34 (16.70,17.98) 
    12 months  14.59 (13.23,15.95) 17.22 (16.49,17.95) 17.12 (16.46,17.79) 
    24 months  15.75 (14.34,17.16) 17.33 (16.58,18.08) 17.16 (16.48,17.85) 
IADLsd  
    Baseline 1.14 (0.87,1.41) 0.30 (0.14,0.46) 0.19 (0.04,0.34) 
    12 months 0.61 (0.36,0.86) 0.24 (0.09,0.39) 0.23 (0.09,0.37) 
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aAPE=Attention, processing speed, and executive function; LM=Learning and memory; z-scores 
standardized to the baseline scores of age- and education-matched controls. 
bBased on FACT-Cog; scores range from 0-148; higher scores indicate better cognition; 
MCID=7-10 points. 
cBased on FACT Functional Well-Being subscale without the question on sleep; scores range 
from 6-24; higher scores indicate better QOL; MCID=2-3 points. 
dBased on OARS-IADLs score; scores range from 1-7; higher scores indicate greater IADL 
disability; MCID=3 points. 
eBased on FACT-Breast Cancer Subscale without the question on pain; scores range from 9-45; 
higher scores indicate better QOL; MCID=2-3 points. 
All results are adjusted for age, race, WRAT score, recruitment site, comorbidity, and APOE 
status. Results for FACT-Breast Cancer Subscale are also adjusted for stage of disease and 
receipt of chemotherapy.  
 
 
 
    24 months 0.45 (0.16,0.75) 0.27 (0.11,0.43) 0.29 (0.14,0.45) 
QOL – breast cancer concernse 
    Baseline 22.87 (21.41,24.33) 29.61 (28.58,30.64) 
n/a     12 months 26.82 (24.95,28.69) 30.03 (28.92,31.14) 
    24 months 27.09 (25.15,29.02) 30.68 (29.53,31.83) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Symptoms in Older Breast Cancer Survivors 28 
 
Table 4. Associations of Symptom Cluster with Survivors’ Breast Cancer-Specific QOL 
FACT-BCS 
Effect β SE 
Intercept 23.90*** 3.02 
Group - High Symptom (vs. low) -6.74*** 0.72 
Time - 12 month 0.43 0.36 
Time - 24 month 1.07** 0.39 
GroupXTime - High Symptom, 12 month 3.53*** 0.97 
GroupXTime - High Symptom, 24 month 3.15** 1.05 
Age 0.10* 0.04 
Race - other race -0.25 0.59 
Cognitive Reserve (WRAT score) 0.00 0.02 
Comorbidity -0.58*** 0.13 
APOE - ε4 positive 0.75 0.57 
Stage - Stage 2-3 -0.52 0.51 
Treatment - Hormone only 0.07 0.55 
*p<0.05, **p<0.01, ***p<0.001 
Reference groups: low symptom for group, baseline for time, White for race, ε4 negative for 
APOE, stage 0-1 for stage, chemotherapy with or without hormone therapy for treatment. The 
model also controlled for study site. Estimates for each group by time interaction represent the 
average difference in rate of change for the high symptom group relative to the low symptom 
group after adjusting for covariates. 
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Figure Legends 
Figure 1. Study flow chart. Those that did not complete an assessment or have missing self-
report data remain eligible to complete the next assessment unless they refuse to continue study 
participation. 
Figure 2. Distributions of T-scores for symptoms by symptom group or control. 
Figure 3a. Mean attention, processing speed, and executive function (APE) domain z-scores by 
symptom or control group, after adjusting for covariates. 
Figure 3b. Adjusted mean learning and memory (LM) domain z-scores by symptom or control 
group. 
Figure 3c. Adjusted mean perceived cognitive function by symptom or control group. 
Figure 4a. Adjusted mean functional well-being by symptom or control group. 
Figure 4b. Adjusted mean instrumental activities of daily living (IADL) disability by symptom or 
control group. 
Figure 4c. Adjusted mean breast cancer quality of life by symptom group. 
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